Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.
Open Access
- 1 May 1992
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 89 (5), 1551-1557
- https://doi.org/10.1172/jci115748
Abstract
The present study was undertaken to evaluate the extent to which an endogenous interleukin-1 (IL-1) response contributes to the hemodynamic and metabolic consequences of sublethal endotoxemia or lethal Gram-negative septic shock. Young, healthy baboons received either a sublethal dose of lipopolysaccharide (LPS) or an LD100 of live Escherichia coli bacteria, and one half of the animals in each group were continuously infused with IL-1 receptor antagonist (IL-1ra). Plasma IL-1 beta was not detected in this model of endotoxemia. Administration of IL-1ra had only minimal effects on the modest hemodynamic and metabolic responses to sublethal endotoxemia, and did not attenuate the plasma cytokine response. In contrast, high circulating levels of IL-1 beta (range 300-800 pg/ml) were seen during lethal E. coli septic shock. IL-1ra treatment significantly attenuated the decrease in mean arterial blood pressure (MAP) (from -72 +/- 8 to -43 +/- 6 mm Hg; P less than 0.05) and cardiac output (from -0.81 +/- 0.17 to -0.48 +/- 0.15 liter/min; P less than 0.05), and significantly improved survival from 43 to 100% at 24 h (P less than 0.05). The plasma IL-1 beta and IL-6 responses to lethal E. coli septic shock were also significantly diminished by IL-1ra treatment (P less than 0.05), whereas tumor necrosis factor-alpha (TNF alpha) concentrations were unaffected. We conclude that an exaggerated systemic IL-1 beta response is characteristic of lethal E. coli septic shock, and contributes significantly to the hemodynamic and metabolic consequences of E. coli septic shock. IL-1ra can significantly attenuate the cytokine cascade and improve survival.Keywords
This publication has 23 references indexed in Scilit:
- Interleukin 1 receptor blockade attenuates the host inflammatory response.Proceedings of the National Academy of Sciences of the United States of America, 1990
- Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.The Journal of Experimental Medicine, 1989
- Two high-affinity interleukin 1 receptors represent separate gene products.Proceedings of the National Academy of Sciences, 1989
- In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice.The Journal of Immunology, 1989
- Detection of Circulating Tumor Necrosis Factor after Endotoxin AdministrationNew England Journal of Medicine, 1988
- Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.The Journal of Experimental Medicine, 1988
- Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.JCI Insight, 1988
- Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemiaNature, 1987
- Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro.The Journal of Immunology, 1987
- Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.The Journal of Experimental Medicine, 1986